These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 24596530)
1. Bortezomib-induced painful neuropathy in patients with multiple myeloma. Bilińska M; Usnarska-Zubkiewicz L; Pokryszko-Dragan A Contemp Oncol (Pozn); 2013; 17(5):421-6. PubMed ID: 24596530 [TBL] [Abstract][Full Text] [Related]
2. Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse. Carozzi VA; Renn CL; Bardini M; Fazio G; Chiorazzi A; Meregalli C; Oggioni N; Shanks K; Quartu M; Serra MP; Sala B; Cavaletti G; Dorsey SG PLoS One; 2013; 8(9):e72995. PubMed ID: 24069168 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405 [TBL] [Abstract][Full Text] [Related]
4. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A Integr Cancer Ther; 2018 Dec; 17(4):1115-1124. PubMed ID: 30295079 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma. Allegra A; Rizzo V; Innao V; Alibrandi A; Mazzeo A; Leanza R; Terranova C; Gentile L; Girlanda P; Allegra AG; Alonci A; Musolino C Arch Med Sci; 2022; 18(3):696-703. PubMed ID: 35591819 [TBL] [Abstract][Full Text] [Related]
6. An Overview of Bortezomib-Induced Neurotoxicity. Meregalli C Toxics; 2015 Jul; 3(3):294-303. PubMed ID: 29051465 [TBL] [Abstract][Full Text] [Related]
7. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066 [TBL] [Abstract][Full Text] [Related]
8. Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. Bechakra M; Nieuwenhoff MD; van Rosmalen J; Groeneveld GJ; Scheltens-de Boer M; Sonneveld P; van Doorn PA; de Zeeuw CI; Jongen JL Mol Pain; 2018; 14():1744806918797042. PubMed ID: 30152246 [TBL] [Abstract][Full Text] [Related]
9. Bortezomib and metformin opposingly regulate the expression of hypoxia-inducible factor alpha and the consequent development of chemotherapy-induced painful peripheral neuropathy. Ludman T; Melemedjian OK Mol Pain; 2019; 15():1744806919850043. PubMed ID: 31041875 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. Velasco R; Alberti P; Bruna J; Psimaras D; Argyriou AA J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S52-S62. PubMed ID: 31647153 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction. Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138 [TBL] [Abstract][Full Text] [Related]
12. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Argyriou AA; Iconomou G; Kalofonos HP Blood; 2008 Sep; 112(5):1593-9. PubMed ID: 18574024 [TBL] [Abstract][Full Text] [Related]
14. Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF-α. Zhao W; Wang W; Li X; Liu Y; Gao H; Jiang Y; Wang Y Ann Hematol; 2019 Dec; 98(12):2793-2803. PubMed ID: 31650289 [TBL] [Abstract][Full Text] [Related]
15. Characterization of a rat model of bortezomib-induced painful neuropathy. Duggett NA; Flatters SJL Br J Pharmacol; 2017 Dec; 174(24):4812-4825. PubMed ID: 28972650 [TBL] [Abstract][Full Text] [Related]
16. Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score. Zaroulis CK; Chairopoulos K; Sachanas SP; Maltezas D; Tzenou T; Pessach I; Koulieris E; Koutra E; Kilindireas K; Pangalis GA; Kyrtsonis MC Leuk Lymphoma; 2014 Oct; 55(10):2277-83. PubMed ID: 24552516 [TBL] [Abstract][Full Text] [Related]
17. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Mohty B; El-Cheikh J; Yakoub-Agha I; Moreau P; Harousseau JL; Mohty M Haematologica; 2010 Feb; 95(2):311-9. PubMed ID: 20139393 [TBL] [Abstract][Full Text] [Related]